AstraZeneca (AZN) stock bolted higher Thursday — and is now within striking distance of a breakout — after its cancer treatments propelled a first-quarter beat. X The Cambridge U.K.-based drugmaker reported almost $5.11 billion in sales of its cancer drugs. Sales rocketed 23% on a strict, as-reported basis and 26% when excluding the impact of